Better Imaging. Better Outcomes.
Providing centralized data management, expert review, and global expertise with AI-enabled imaging solutions for today’s clinical trials.
Compliance & Trust
Our platform and services meet the highest compliance standards, ensuring complete regulatory alignment.
FDA 21 CFR Part II
ISO13485
GDPR
HIPPA
SOC 2
Experience Matters
Providing standardized image assessments across a spectrum of therapeutic indications for smarter decisions, quicker studies, and reliable trial endpoints.
Musculoskeletal (MSK)
Osteoarthritis & Cartilage Disease
We drive osteoarthritis trials with advanced imaging—X-ray, MRI (3D, T2 mapping, dGEMRIC), CT, and ultrasound—to assess cartilage, bone, and joint health. Using OARSI, MOAKS, WORMS, and Kellgren-Lawrence scoring, we provide precise evaluation of joint damage and repair, accelerating musculoskeletal therapy development.
Bone Health & Osteoporosis
We deliver expert imaging solutions for bone health and osteoporosis trials using DXA, QCT, X-ray, and MRI to assess bone density, structure, and microarchitecture. Leveraging vertebral fracture grading, trabecular bone score, and advanced biomarkers, we provide robust, regulatory-grade endpoints that support safe and efficient therapy development.
Ankylosing Spondylitis
Using X-ray, MRI (STIR and dynamic contrast), CT, and ultrasound, our experts apply established scoring systems, including the New York criteria, SASSS, BASRI, and MRI Spine Score, to accurately measure inflammatory and structural changes, providing reliable imaging endpoints that advance therapeutic development.
Rheumatoid Arthritis
Our team of experts provides advanced imaging for rheumatoid arthritis clinical trials, utilizing X-ray, MRI, DCE-MRI, CT, and PET. We have developed innovative scoring systems to accurately measure synovial inflammation and bone erosions, supporting leading therapies from early development through phase 3 and enabling efficient drug approvals with reliable, objective imaging endpoints.
Psoriasis & PsA
Our team applies X-ray, MRI, Whole-Body MRI, DCE-MRI, ultrasound, and CT to assess skin, joint, and entheseal involvement with validated scoring systems. These precise, reliable imaging endpoints drive the development and regulatory approval of innovative therapies.
Scleroderma
Our team supports scleroderma trials with advanced imaging, including MRI, ultrasound, CT, X-ray, and novel tools like DAVIX to assess skin, vasculature, and organ involvement. Using mRSS, DAVIX, and quantitative scores, we deliver validated endpoints for drug development and disease monitoring.
Myositis
We support myositis trials with advanced imaging, including whole-body MRI, ultrasound, and PET, to evaluate muscle inflammation and damage. Using cutting-edge protocols and biomarkers, we deliver sensitive, objective, and reproducible endpoints for therapy development.
Obesity / Metabolic
Obesity
Using MRI, CT, DEXA, ultrasound, and PET, we assess organ health, body composition, and metabolic status. Our imaging solutions quantify fat, muscle, and organ changes, enabling accurate efficacy, safety, and patient-focused outcomes in metabolic drug development.
Liver Diseases
We support liver disease and MASH/NASH trials with standardized MRI (MRI-PDFF, MRE), CT, ultrasound, and elastography protocols for non-invasive assessment of fat, fibrosis, and inflammation. Our solutions enable precise patient selection, monitoring, and robust efficacy and safety endpoints while reducing reliance on biopsy.
Rare Metabolic Disorders
We provide FDA/EMA regulatory medical imaging solutions for rare metabolic disorder trials. Using MRI, MR spectroscopy, PET, CT, and ultrasound, we assess organ involvement, metabolic function, and tissue pathology. Our protocols support early diagnosis, accurate treatment evaluation, and ongoing safety monitoring, delivering high-quality, reproducible endpoints that streamline regulatory submissions and accelerate drug development.
Rare Diseases/Inflammation & Immunology
Rare Genetic Disorders
We provide specialized imaging for rare genetic disorder trials, using multiparametric MRI, PET, CT, and advanced analysis with AI and radiomics. We develop disease- and trial-specific protocols to assess organ involvement, tissue pathology, and metabolic status, delivering precise, reproducible endpoints for diagnosis, therapy evaluation, and safety monitoring across global studies.
Duchenne Muscular Dystrophy
We offer expert imaging for Duchenne muscular dystrophy trials, using noninvasive MRI protocols (Dixon imaging, T2 mapping, spectroscopy) to measure muscle volume, fat infiltration, and disease progression. Our standardized approach provides sensitive biomarkers that correlate with functional outcomes, enabling early detection of therapy effects and minimizing the need for invasive muscle biopsies.
Systemic Lupus Erythematosus
We deliver advanced imaging solutions for SLE trials, using MRI, ultrasound, and CT to objectively assess joints, organs, and vascular involvement. Our team applies validated scoring systems and quantitative biomarkers to track inflammation and tissue damage, providing sensitive efficacy measures and robust data to support lupus drug development.
CAR-T in Autoimmune Diseases
Image Analysis Group supports CAR-T trials in autoimmune diseases with tailored MRI, CT, ultrasound, and PET protocols to monitor organ involvement, inflammation, and safety. We provide baseline staging, response assessment, and detection of complications like cytokine release syndrome and neurotoxicity, delivering sensitive, regulatory-grade imaging endpoints from early to pivotal phases.
Oncology
Glioblastoma
We help advance glioblastoma trials with cutting-edge MRI (3D T1, FLAIR, DWI, perfusion), PET, and novel imaging biomarkers. Using RANO/iRANO criteria, radiomics-driven endpoints, and AI, we enable early therapy response assessment and precise tumor characterization, supporting innovative neuro-oncology research.
Hematologic Malignancies (Leukemia, Lymphoma, Myeloma)
We deliver expert imaging for hematologic malignancies, leukemia, lymphoma, and myeloma, using FDG PET/CT, whole-body MRI, and low-dose CT. Applying Deauville, Cheson, and IMWG criteria, we support disease staging, therapy response, and minimal residual disease detection, providing robust quantitative endpoints to accelerate hematology drug development.
Breast Cancer
We provide advanced imaging solutions for breast cancer trials, using mammography, ultrasound, volumetric ultrasound, MRI (DCE-MRI, DWI, MRS), and PET. By applying BIRADS, RECIST 1.1, and other scoring systems, we track lesion characteristics, treatment response, and staging, delivering precise, multi-modality endpoints to accelerate breast cancer therapy development.
Colorectal Cancer
We specialize in colorectal cancer imaging for clinical trials, using imaging modalities: MRI, CT, PET, high-resolution and diffusion-weighted MRI, PET, and advanced functional techniques to evaluate tumor burden, staging, and treatment response. Applying RECIST, volumetric, and radiomics metrics, we deliver precise, data-driven endpoints to support drug development and regulatory approval.
Head and Neck Cancers
We specialize in head and neck cancer imaging for clinical trials, using CT, anatomical and multiparametric MRI, DCE- and diffusion imaging, PET/CT, and PET/MRI. Leveraging RECIST 1.1, iRECIST, SUV, and volumetric assessments, we provide precise characterization of tumor extent, nodal involvement, perineural spread, and therapy response to generate robust clinical endpoints.
Lung Cancer
We provide specialized imaging for lung cancer trials, using CT, PET/CT, MRI (including DWI and whole-body MR), and advanced protocols for accurate tumor detection, staging, and therapy monitoring. Applying RECIST 1.1, iRECIST, and volumetric assessments, we deliver robust clinical endpoints, support optimal patient selection, and accelerate evaluation of novel therapies.
Pancreatic Cancer
We specialize in pancreatic cancer imaging for clinical trials, using advanced CT, multiparametric MRI (DCE-MRI, diffusion-weighted), endoscopic ultrasound, and PET. We provide precise tumor detection, vascular and nodal staging, and robust therapy response assessment, supporting confident patient selection and the development of innovative treatments.
Prostate Cancer
We offer comprehensive FDA/EMA regulatory medical imaging for prostate cancer trials, using multiparametric MRI, PSMA PET/CT, bone scan, CT, and advanced ultrasound to assess detection, staging, and therapy response. Applying RECIST 1.1, iRECIST, PI-RADS, PET SUV, and volumetric metrics, we deliver precise, validated endpoints to accelerate prostate cancer drug development.
Sarcomas
We use multiparametric MRI (DCE-MRI, diffusion), CT, and functional PET (FDG, FAPI) to assess sarcoma. Applying Choi, RECIST 1.1, volumetric criteria, radiomics, and molecular imaging biomarkers, we provide objective evaluation of sarcoma subtypes, therapy response, and robust, data-driven trial endpoints.
Other
Alzheimer’s Disease
We deliver expert imaging for Alzheimer’s disease trials, using standardized MRI (structural, volumetric, DWI, FLAIR), amyloid and tau PET, and CT to support efficacy and safety assessment. Our protocols enable accurate patient selection, sensitive tracking of disease progression, and monitoring of adverse events, including ARIA, microhemorrhage, and edema, ensuring early risk detection, regulatory compliance, and reliable trial outcomes.
Parkinson’s Disease
We provide specialized imaging for Parkinson’s disease trials, using standardized MRI to track brain structure and volumetric changes, along with SPECT (DaTSCAN) and PET to assess presynaptic dopaminergic deficits. Our protocols support accurate patient selection, sensitive monitoring of disease progression, and safety oversight, delivering reliable endpoints for regulatory and pivotal studies.
Multiple Sclerosis
For multiple sclerosis trials, Image Analysis Group provides expert imaging using optimized MRI protocols (T1, T2, FLAIR, diffusion) to quantify new/enlarging lesions, gadolinium-enhancing activity, and brain/spinal cord atrophy. Centralized reads deliver objective, reproducible endpoints, enabling sponsors to demonstrate efficacy, safety, and long-term impact of MS therapies.
Traumatic Brain Injury
We provide FDA/EMA regulatory medical imaging for traumatic brain injury (TBI) trials, using CT for rapid detection of hemorrhage, mass effect, and fractures, and advanced MRI (DTI, SWI, FLAIR) to assess microbleeds, diffuse axonal injury, edema, and contusions. Our standardized protocols ensure consistent image acquisition and interpretation, enabling accurate injury classification, monitoring of progression, and sensitive safety and efficacy assessment—supporting reliable endpoints and data-driven insights across acute and long-term TBI studies.
Reproductive Health
Using high-resolution ultrasound, MRI, and AI-driven analysis, Image Analysis Group supports non-invasive assessment of uterine, ovarian, and embryonic health, pregnancy monitoring, and fertility outcomes. Our DYNAMIKA platform streamlines multi-center studies with centralized data management and advanced image analysis, delivering precise, regulator-ready endpoints that enable smarter study design and progress across reproductive medicine, from preconception and IVF to maternal health.
Abdominal Imaging
Leveraging high-resolution MRI, CT, ultrasound, and AI-driven analysis, we support non-invasive assessment of liver, pancreas, kidneys, and gastrointestinal health and fat fraction analysis for clinical trials. We streamline multi-center studies with centralized data management and advanced image analysis, delivering precise, regulator-ready endpoints that enable accurate monitoring of disease progression, therapy response, and safety, accelerating drug development across hepatology, gastroenterology, and renal medicine.
Why Work with IAG?
Worldclass Medical Imaging Expertise in Trials
Comprehensive imaging expertise
We cover all major imaging modalities including MRI, CT, PET, ultrasound, and X-ray. Our standardized protocols ensure consistent, high-quality data from all study sites, delivering reliable, actionable insights that drive clinical trial success.
Global network of radiology and therapeutic experts
Partner with us to access a multi-site global clinical trial imaging network of expert radiology readers, therapeutic specialists and KOLs and scientific expertise. Every image is interpreted with precision to provide clinical insight and ensure reliable trial outcomes.
Collaborative approach with clinical and scientific teams
We collaborate with a strong network of clinical scientists and operational teams, fostering open communication and shared insights. This partnership ensures imaging strategies are fully aligned with your trial objectives, enhancing outcomes and maximizing scientific value at every stage.
Innovative solutions for every trial phase
We support trials at every stage, from early phase to the development of imaging biomarkers and companion diagnostics to approved regulatory assessments in global Phase III studies. With approximately 20 years of experience, we know what regulators require and develop strategies to enable success. Our approach helps speed up timelines while keeping data accurate and compliant.
Dynamika: One Solution for All Imaging Needs
Scalable, secure, and built for trials of all sizes
DYNAMIKA centralizes every step of imaging data management, from capture and de-identification to transfer and review, into one secure, easy-to-use platform. Designed for all studies, it scales effortlessly, safeguards sensitive data with enterprise-grade security, and complies with international privacy and regulatory standards. Seamless integration with eClinical tools, EDCs, and sponsor systems ensures smooth data exchange and streamlined trial operations.
QC and real-time oversight
DYNAMIKA ensures every image meets protocol standards through a mutli-step quality control and resolution process. Data is anonymized and validated as it’s uploaded, reducing errors and delays. Real-time dashboards give Sponsors full visibility into site performance, data quality, and readiness for reads, ensuring reliable results and faster trial progress.
Central review with built-in eCRFs and workflow management.
DYNAMIKA centralizes imaging review with built-in eCRFs and adjudication. Expert readers assess data remotely, entries are validated instantly, and disagreements trigger a transparent adjudication workflow. Every step is documented for compliance, ensuring accurate, regulator-ready imaging endpoints.
AI-enabled workflows
DYNAMIKA integrates AI-enabled imaging intelligence for structured quality control, anonymization, and advanced image analysis. With proven experience in global trials, IAG supports seamless validation, and central review across therapeutic areas. Cloud-based workflows streamline data, enhance reproducibility, and ensure regulatory-ready, AI-enabled trial processes and clinical trial endpoints.
Configurable workflows & role-based access
DYNAMIKA lets you configure workflows and assign role-based permissions, tailoring imaging processes to your trial and team. This ensures efficient operations while maintaining strict oversight and data integrity.
Operational Excellence: Ensuring Reliable, High-Quality Imaging Trials
Experienced project team
IAG’s dedicated project team brings deep operational, technological, and clinical expertise to every trial. Through meticulous planning, proactive communication, and real-time support, they ensure efficient operations, high-quality data, and seamless coordination between sites and sponsors, helping trials stay on track and deliver reliable outcomes.
Dedicated support for sites and investigators
IAG provides hands-on training, real-time troubleshooting, and clear guidance to investigators and site staff at every stage. With intuitive tools, standardized protocols, and 24/7 expert support, we minimize site burden, ensure high-quality imaging data, and foster strong collaboration, allowing sites to focus on patient care and trial success.
Geographical reach
IAG provides comprehensive support for clinical trials across North America, Europe, Asia-Pacific, Latin America, and beyond. Our established site network enables rapid activation, efficient imaging logistics, and real-time regional support. Our expertise helps sponsors run multi-center, multi-country studies smoothly, ensuring consistent, high-quality imaging and faster global enrollment.
Minimizing site burden
IAG’s intuitive workflows, streamlined platforms, and comprehensive training reduce administrative workload and simplify imaging processes. Automated data capture, clear communication, and proactive support help sites focus on patient care while delivering high-quality, on-time imaging data, making trial participation efficient and stress-free.
Let’s Speak!
Speak with a member of our team
Publicly announced partnerships
For nearly 20 years, we’ve helped sponsors accelerate drug development by combining scientific expertise, operational excellence, and innovative technology.
What we can do for You:
Talk to IAG Team
If you are planning a clinical trial which will use imaging to assess safety and efficacy of your new drug candidate, share your challanges with our team.
More Questions?
How experienced is IAG in managing imaging for clinical trials?
IAG combines its proprietary DYNAMIKA platform with in-house radiology and therapeutic expertise to deliver tailored imaging strategies across oncology, immunology, neurology, rare diseases, and more. With real-time quality control, AI-powered endpoints, and a quality-certified global network, IAG helps reduce sample sizes, accelerate timelines, and provide reliable, regulator-ready imaging data.
How many trials has IAG successfully supported?
Since 2007, IAG has supported over 700 global clinical trials across all phases and therapeutic areas. Our expertise and advanced imaging solutions help optimize trial workflows, accelerate timelines, and support regulatory success for novel therapies.
How does IAG use AI to improve imaging analysis and trial endpoints?
IAG integrates AI and advanced analytics via its DYNAMIKA platform to transform image review and endpoint assessment. Key capabilities include:
– AI-Powered Endpoints: Accelerate detection of treatment effects and improve trial reliability.
– Automated, Quantitative Analysis: Extract imaging biomarkers to optimize patient selection and forecast outcomes.
– Radiomics & Pathomics: Combine image and pathology data for predictive, personalized insights.
– Early, Sensitive Detection: Identify subtle disease changes often missed by conventional review.
– Centralized, Blinded Reads: Ensure consistent, reproducible endpoints across multi-site trials.
– Regulatory Compliance: Analytics and review meet standards like 21 CFR Part 11 and ISO 13485.
How does IAG ensure imaging data is secure and compliant?
IAG combines industry-leading certifications with advanced technology safeguards to deliver a secure, compliant, and reliable imaging environment. Key measures include:
– Certifications: SOC II Type I, BSI, ISO 13485, and 21 CFR Part 11 ensure global regulatory compliance and operational security.
– Automated Data Anonymization: Protects patient privacy and meets data protection laws.
– Centralized QC & Audit Trails: Guarantees data integrity, traceability, and consistent quality.
– Secure Cloud Infrastructure: Provides controlled, global access for collaboration while safeguarding sensitive data.
– Ongoing Oversight: Regular audits ensure continuous compliance and improvement.
Where does IAG operate and support clinical trials?
IAG operates worldwide, with offices, teams, and partnerships across the UK, EU, USA, India, China, Australia, Africa, and beyond.
– UK & Europe: Headquarters in London with full operational and project management support.
– USA: Rapidly growing presence supporting AI-driven imaging trials.
– Asia-Pacific: Teams in India and partnerships in China and Australia for seamless regional support.
– Global Site Network: Well-connected sites and radiology readers enable fast setup, efficient data collection, and smooth multi-center execution.
How does IAG’s pricing work, and what value does it provide?
IAG offers flexible, tailored pricing to meet the specific needs of each trial while optimizing budgets without compromising quality. Costs are typically based on:
– Trial Complexity & Phase: Phase I–III or real-world studies
– Sites & Patients: Number of locations and participants
– Imaging Requirements: Modalities, endpoints, and customization
– Service Scope: Site setup, data management, central reads, regulatory support, and system integration